

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/188856 A1

(43) International Publication Date
15 September 2022 (15.09.2022)

(51) International Patent Classification:

A61K 39/395 (2006.01) *A61P 35/00* (2006.01)
G01N 33/68 (2006.01)

(21) International Application Number:

PCT/CN2022/080297

(22) International Filing Date:

11 March 2022 (11.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/080142

11 March 2021 (11.03.2021) CN

PCT/CN2022/076516

16 February 2022 (16.02.2022) CN

(71) Applicants: **SHANGHAI JIAO TONG UNIVERSITY** [CN/CN]; Suite 327, Med-X Academy, 1954 Huashan Road, Xuhui District, Shanghai 200031 (CN). **SUZHOU TRANSCENTA THERAPEUTICS CO., LTD.** [CN/CN]; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN).

(72) Inventors: **ZHU, He**; Suite 327, Med-X Academy, 1954 Huashan Road, Xuhui District, Shanghai 200031 (CN). **QIAN, Xueming**; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN). **GAO, Weiqiang**; Suite 327, Med-X Academy, 1954 Huashan Road, Xuhui District, Shanghai 200031 (CN). **CHENG, Chaping**; Suite 327, Med-X Academy, 1954 Huashan Road, Xuhui District, Shanghai 200031 (CN). **WANG, Jinming**; Suite 327, Med-X Academy, 1954 Huashan Road, Xuhui District, Shanghai 200031 (CN). **SUN, Di**; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN).

(74) Agent: **JUN HE LAW OFFICES**; 20/F, China Resources Building 8 Jianguomenbei Avenue, Beijing 100005 (CN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHOD OF TREATING DISEASES USING GREMLIN1 ANTAGONISTS

(57) Abstract: The present disclosure provides herein treatment methods for GREM1-related disease or condition characterized in deficient in PTEN and/or p53. Also provided by the present disclosure are treatment methods for castration-resistant prostate cancers

WO 2022/188856 A1